Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | NPC1 | O15118 | 3/20 | 0.72 |
| ▸ | POLB | P06746 | 2/20 | 0.72 |
| ▸ | BCHE | P06276 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.61 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.61 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | AR | P10275 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TXN | P10599 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8429703 | 0.87 | RAB9A (0.77) | RAB9ASMN1; SMN2NPC1POLBBCHE | |
| SCHEMBL12956345 | 0.87 | RAB9A (0.77) | RAB9ASMN1; SMN2NPC1POLBBCHE | |
| SCHEMBL13850687 | 0.86 | RAB9A (0.75) | RAB9ASMN1; SMN2NPC1POLBBCHE | |
| Hydrochloric Acid SCHEMBL9096594 | 0.86 | RAB9A (0.75) | RAB9ASMN1; SMN2NPC1POLBBCHE | |
| SCHEMBL7284923 | 0.84 | SMN1; SMN2 (0.73) | RAB9ASMN1; SMN2NPC1POLBBCHE | |
| SCHEMBL7284917 | 0.84 | RAB9A (0.73) | RAB9ASMN1; SMN2NPC1POLBBCHE | |
| SCHEMBL12195165 | 0.83 | RAB9A (0.71) | RAB9ASMN1; SMN2NPC1POLBBCHE | |
| SCHEMBL10821280 | 0.82 | SMN1; SMN2 (0.69) | RAB9ASMN1; SMN2NPC1POLBBCHE | |
| SCHEMBL31175737 | 0.81 | BCHE (0.73) | RAB9ASMN1; SMN2NPC1POLBBCHE | |
| SCHEMBL7998438 | 0.81 | BCHE (0.73) | RAB9ASMN1; SMN2NPC1POLBBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245231-A1 | ACTIVE SUBSTANCE AND PHARMACEUTICAL COMPOSITION FOR TREATING ALCOHOL DEPENDENCE, AND A METHOD FOR OBTAINING AND THE USE OF SAID ACTIVE SUBSTANCE | ALLA CHEM, LLC (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110245231-A1 | ACTIVE SUBSTANCE AND PHARMACEUTICAL COMPOSITION FOR TREATING ALCOHOL DEPENDENCE, AND A METHOD FOR OBTAINING AND THE USE OF SAID ACTIVE SUBSTANCE | ALLA CHEM, LLC (US) | 2011-10-06 | — | — | US | disclosed |
| WO-2010074607-A2 | ACTIVE SUBSTANCE AND PHARMACEUTICAL COMPOSITION FOR TREATING ALCOHOL DEPENDENCE, AND A METHOD FOR OBTAINING AND THE USE OF SAID ACTIVE SUBSTANCE | АЛЛА XEM, ЛЛС (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20090118334-A1 | METHOD OF TREATMENT OF CARDIAC AND/OR RENAL FAILURE USING A CALCIUM CHANNEL BLOCKER AND AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR OR AN ANGIOTENSIN II RECEPTOR BLOCKER | DIAKRON PHARMACEUTICALS, INC. (US) | 2009-05-07 | — | — | US | disclosed |
| US-7235570-B2 | 1,4-dihydropyridine and pyridine compounds as calcium channel blockers | VITTAL MALLYA SCIENTIFIC RESEARCH (IN) | 2007-06-26 | — | — | US | disclosed |
| US-6852742-B2 | 1,4-dihydropyridine and pyridine compounds as calcium channel blockers | VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) | 2005-02-08 | — | — | US | disclosed |
| US-6852742-B2 | 1,4-dihydropyridine and pyridine compounds as calcium channel blockers | VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) | 2005-02-08 | — | — | US | disclosed |
| US-5942641-A | TREATMENT OF ALZHEIMER'S DISEASE, NERVOUS SYSTEM DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1999-08-24 | — | — | US | disclosed |
| EP-0655992-B1 | FLUORENONE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND CENTRAL OR PERIPHERAL NERVE DEGENERATION REPAIR AND PROTECTIVE AGENT | OTSUKA PHARMA CO LTD (JP) | 1998-11-04 | — | — | EP | disclosed |
| EP-0791570-A1 | Fluorenone derivatives, process for preparing the same and central or peripheral nerve degeneration repair and protective agent | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-27 | — | — | EP | disclosed |
| EP-0655992-A1 | FLUORENONE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND CENTRAL OR PERIPHERAL NERVE DEGENERATION REPAIR AND PROTECTIVE AGENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-06-07 | — | — | EP | disclosed |
| WO-1995000468-A1 | FLUORENONE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND CENTRAL OR PERIPHERAL NERVE DEGENERATION REPAIR AND PROTECTIVE AGENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118334-A1 | METHOD OF TREATMENT OF CARDIAC AND/OR RENAL FAILURE USING A CALCIUM CHANNEL BLOCKER AND AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR OR AN ANGIOTENSIN II RECEPTOR BLOCKER | AGTR2, ACE, AGTR1 | RAB9A 2789/4885SMN1; SMN2 3210/4885NPC1 2119/4885 |
| US-20110245231-A1 | ACTIVE SUBSTANCE AND PHARMACEUTICAL COMPOSITION FOR TREATING ALCOHOL DEPENDENCE, AND A METHOD FOR OBTAINING AND THE USE OF SAID ACTIVE SUBSTANCE | ADH1C, ADH1A, ADH5 | RAB9A 4196/4885SMN1; SMN2 3094/4885NPC1 1472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.